ERBB2 and breast carcinoma: In agreement with those data, inhibition of CDK4/CDK6 using PD0332991 suppressed the proliferation of luminal estrogen receptor-positive human breast cancer cell lines and exhibited synergistic effects when combined with tamoxifen and trastuzumab against ER+ and HER2− amplified cell lines, respectively57.